Jazz Pharmaceuticals (FRA:J7Z) FFO


FRA:J7Z Jazz Pharmaceuticals PLC FRA:J7Z
69 GF Score
Price €209.90
GF Value €131.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

FRA:J7Z
69GF Score
Jazz Pharmaceuticals PLC FRA:J7Z
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of €209.90 is trading 59.6% above its estimated GF Value™ of €131.55. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:J7Z:

  • FFO:
  • GF Value™: €131.55 vs. price of €209.90 (59.6% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
69GF Score

Get the complete analysis for FRA:J7Z

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€209.90
Price
€131.55
GF Value